Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 4Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1CNS 1

Conditions

Breast Neoplasms 433Carcinoma, Non-Small-Cell Lung 372Neoplasms 326Prostatic Neoplasms 244Leukemia, Myeloid, Acute 231Multiple Myeloma 230Neoplasm Metastasis 215Melanoma 202Lung Neoplasms 178Leukemia 172Lymphoma 170Colorectal Neoplasms 157Pancreatic Neoplasms 151Lymphoma, Non-Hodgkin 150Recurrence 149Ovarian Neoplasms 146Leukemia, Lymphocytic, Chronic, B-Cell 134Precursor Cell Lymphoblastic Leukemia-Lymphoma 131Myelodysplastic Syndromes 121Carcinoma, Renal Cell 121Lymphoma, Large B-Cell, Diffuse 111Lymphoma, Follicular 108Brain Neoplasms 101Squamous Cell Carcinoma of Head and Neck 96Head and Neck Neoplasms 96Glioblastoma 92Urinary Bladder Neoplasms 88Carcinoma, Hepatocellular 80Hodgkin Disease 73Colonic Neoplasms 73

Interventions

Sunitinib 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Has results × von Hippel-Lindau Disease × Clear all
NCT00330564 2024-06-27

Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow

M.D. Anderson Cancer Center

Phase 2 Terminated
15 enrolled 5 charts
Genitourinary

Carcinoma, Renal Cell, Cysts, von Hippel-Lindau Disease, Neoplasms, Hemangioblastoma

NCT01266070 2017-02-13

TKI 258 in Von Hippel-Lindau Syndrome (VHL)

M.D. Anderson Cancer Center

Phase 2 Terminated
6 enrolled 5 charts
CNS

von Hippel-Lindau Disease, Central Nervous System Neoplasms, Hemangioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡